Massimo Dominici
Professor at the University Hospital of Modena and Reggio Emilia; and Scientific Founder of Rigenerand
Meet Massimo Dominici
“COVID-19 has led to challenges with clinical trials; almost 1500 trials have reported delays due to the pandemic. This is particularly true for phase I studies. For those, almost half of the trials that have been delayed have had a special impact in oncology. Considering that cell and gene therapies have their big fraction of investigations in that phase, this could have a relevant impact on the field. The big challenge – but also opportunity – for the industry is how to adapt to the current and possibly enduring situation and how to conceive new ways to conduct trials, accounting for regulatory frameworks, new technologies, and new needs.”